Bianca Weinstock-Guttman, Katelyn Kavak, Caila Vaughn, et al. Discontinuation of disease modifying therapies in stable MS patients is associated with disability progression regardless of age. AAN 2018, S8.008.
Vergoeding selumetinib (Koselugo) voor kinderen met neurofibromatose type 1
mei 2024